NeuroMab™ Anti-Tenascin C Antibody(NRP-0422-P756)

Figure 1 shows the binding of anti-TNC A2 antibody 2B10 as wild type (wt) and glycoengineered (ge) versions to TNC A2 on U87MG cells.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.

Figure 2 shows the binding of 2B10-derived human IgG to TNC A2 expressed on U87MG glioblastoma tumor cells as determined by flow cytometry.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.

Figure 3 shows immunohistochemical images of human tissue stained with 2B10-mouse IgG at 100× (left panel) and 400× (middle panel) magnifications.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.

Figure 4 shows the SPR-based kinetic analysis of the binding of 2B10 anti-TNC A2 Fab fragment to human TNC A2.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.

Figure 5 shows the SPR-based kinetic analysis of 2B10 anti-TNC A2 Fab fragments binding cynomolgus monkey TNC A3.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.

Figure 6 shows the SPR-based kinetic analysis of the binding of the 2B10 anti-TNC A2 Fab fragment to murine TNC A3.

Staining with an isotype control antibody is shown at 100X magnification (right panel). Top: normal tissue, bottom: tumor tissue from the brain.